Status:
COMPLETED
Hospital at Home at EOL in Heme Malignancies
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
Medically Home
Conditions:
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is evaluating an intervention, which the investigators call "Optimize End of Life (EOL) Care at Home," that entails remote patient monitoring and home-based supportive care for patients wit...
Detailed Description
This research study is a single arm pilot feasibility study, which is the first-time investigators are examining this care at home intervention in patients with advanced hematologic malignancies. The...
Eligibility Criteria
Inclusion
- age 18 or older
- diagnosed with relapsed or refractory hematologic malignancy
- must be receiving treatment with non-curative intent or supportive care alone based on the intent of chemotherapy as reported in order entry or Electronic Health Record
- deemed eligible to receive EOL care at home based on the primary oncologist's assessment
- Able to communicate and respond to questionnaires in English or with the assistance of an interpreter.
- residing within 50 miles of MGH. Of note, patients requiring supportive transfusions in the oncology clinic will still be eligible to participate.
Exclusion
- Those with uncontrolled psychiatric illness or impaired cognition interfering with their ability to understand study procedures and provide written informed consent as determined by the primary oncologist.
Key Trial Info
Start Date :
February 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2025
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04690205
Start Date
February 26 2021
End Date
July 1 2025
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114